DuPont Applied BioSciences has turned to MBI International to join the DuPont team in evaluating the commercial viability of an important bio-based product line. MBI International is a leader in bridging the gap between research and commercialization through collaborative de-risking of bio-based technologies. MBI’s unique “Collaborative De-Risking” process systematically addresses technological uncertainties, which impede new technologies from getting to market.
LANSING, Mich. (Business Wire EON) December 2, 2008 -- "We are very excited that DuPont Applied BioSciences has chosen MBI as a partner to help de-risk this important new product line," stated Dr. Bobby Bringi, recently appointed President of MBI International. "We had the opportunity to work with DuPont Applied BioSciences on an initial phase of this project, and are proud that they have chosen to extend this partnership with MBI."
MBI International fits a unique niche in the marketplace. Virtually all bio-based technology developments that come from the lab need to go through a process development and scale-up stage to determine commercial viability. Once the uncertainties or risks associated with early technological developments are mitigated via de-risking, a company like DuPont Applied BioSciences is better positioned to make product-related investments.
MBI has built a multi-disciplinary team of scientists and engineers, as well as the required pilot-plant facilities, to work collaboratively with industry partners to help address the risks associated with bringing bio-based technologies to market. MBI also provides connectivity with both Michigan State University and the greater university research community to help solve complex problems.
"DuPont Applied BioSciences is pleased to continue our collaboration with MBI on this important new product line," stated Scott Cunningham, Business Development Manager – DuPont Applied BioSciences. "MBI's well rounded expertise, operational flexibility and excellent facilities allowed us to successfully complete Phase I of the project. We are confident that MBI will help us to evaluate the critical path of this technology and identify opportunities and threats to scale-up and commercialization."
"DuPont is a world leading market-driven, science-based products company, so we are pleased they have chosen to continue working with our team," states Bringi. "De-risking high-technology developments is like building a bridge to the market. It requires experienced partners to work in collaboration with one another at each stage in the process from the lab through scale-up and then to the market. From our point of view, this relationship helps validate the strategic position we have chosen for MBI."
MBI partners with universities and companies involved in sustainable technologies to bridge the gap between research and commercial applications. With over 25 years experience in fermentation technologies and process scale-up, MBI bundles a full spectrum of science, engineering, operational, and business expertise with an integrated infrastructure from laboratory bench to pilot-plant. MBI's focus is Industrial or White Biotechnology, which refers to the production of fuels, chemicals, polymers, proteins and other materials from renewable resources. Please visit www.mbi.org for more information.
Read the full story at http://www.prweb.com/releases/dupont_applied/applied_biosciences/prweb1694764.htm
Copyright©2008 Vocus, Inc.
All rights reserved